Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
20°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neurocrine Bioscienc
(NQ:
NBIX
)
126.70
-0.09 (-0.07%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Neurocrine Bioscienc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Confidence Boost From Ingrezza Sales: Analyst Upgrades Neurocrine Biosciences
July 06, 2023
BMO Capital Markets has upgraded Neurocrine Biosciences Inc (NASDAQ: NBIX) from Underperform to Market Perform, with a price target of $96,
Via
Benzinga
What To Know About BMO Capital's Upgrade of Neurocrine Biosciences
July 06, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
July 06, 2023
Via
Benzinga
Expert Ratings for Neurocrine Biosciences
June 30, 2023
Via
Benzinga
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences
June 05, 2023
Via
Benzinga
Neurocrine Biosciences's Return On Capital Employed Overview
May 08, 2023
Via
Benzinga
Neurocrine Biosciences Clocks 35% Revenue Growth In Q1, Misses On Bottom-Line Performance
May 03, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
May 04, 2023
Via
Benzinga
Neurocrine Biosciences: Q1 Earnings Insights
May 03, 2023
Via
Benzinga
Neurocrine Biosciences's Earnings: A Preview
May 02, 2023
Via
Benzinga
3 Pharma Stocks That Could See a Surge in Demand in 2023
April 24, 2023
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead
Via
InvestorPlace
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences
April 17, 2023
Via
Benzinga
Expert Ratings for Neurocrine Biosciences
March 30, 2023
Via
Benzinga
Analyst Expectations for Neurocrine Biosciences's Future
March 03, 2023
Via
Benzinga
Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets
February 06, 2023
Neurocrine also topped fourth-quarter revenue expectations on Monday.
Via
Investor's Business Daily
Neurocrine Biosciences Earnings Preview
February 03, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
March 30, 2023
Via
Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
March 13, 2023
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
March 03, 2023
Via
Benzinga
Why Voyager Therapeutics Stock Is Sinking This Week
January 20, 2023
Investors are taking profits on this red-hot stock this week.
Via
The Motley Fool
Earnings Scheduled For February 6, 2023
February 06, 2023
Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion.
Via
Benzinga
Five Best And Worst Performing Healthcare Stocks In January 2023
February 05, 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
February 03, 2023
Via
Benzinga
7 A-Rated Stocks to Buy for Less Than $25
January 24, 2023
These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.
Via
InvestorPlace
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
January 13, 2023
Sharp Tesla price cuts and some notable earnings were in focus.
Via
Investor's Business Daily
Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal
January 09, 2023
Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today.
Via
InvestorPlace
Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies
January 09, 2023
Via
Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
December 25, 2022
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.
Via
Benzinga
Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally
December 17, 2022
UnitedHealth is among medical stocks holding key support.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.